

RESEARCH

Open Access



# Quercetin alleviates cyclophosphamide-induced premature ovarian insufficiency in mice by reducing mitochondrial oxidative stress and pyroptosis in granulosa cells

Yun Chen<sup>†</sup>, Ying Zhao<sup>†</sup>, Chenyun Miao<sup>†</sup>, Liuqing Yang, Ruye Wang, Bixia Chen and Qin Zhang\*

## Abstract

**Background:** Exposure to cyclophosphamide (CTX) induces premature ovarian insufficiency (POI). Quercetin is a natural flavonoid that exhibits anti-inflammatory and antioxidant properties, and its antioxidant activity is correlated with POI. However, the mechanism underlying its protective role in CTX-induced ovarian dysfunction is unclear. This study aimed to explore whether quercetin can protect ovarian reserves by activating mitochondrial biogenesis and inhibiting pyroptosis.

**Methods:** Thirty-six female C57BL/6 mice were randomly subdivided into six groups. Except for the control group, all groups were injected with 90 mg/kg CTX to establish a POI model and further treated with coenzyme 10 or various doses of quercetin. The mice were sacrificed 48 h after 10 IU pregnant mare serum gonadotropin was injected four weeks after treatments. We used enzyme-linked immunosorbent assays to detect serum hormone expression and light and transmission electron microscopy to assess ovarian tissue morphology and mitochondria. Additionally, we tested oxidant and antioxidant levels in ovarian tissues and mitochondrial function in granulosa cells (GCs). The expression of mitochondrial biogenesis and pyroptosis-related proteins and mRNA was analyzed using western blotting and RT-qPCR.

**Results:** Quercetin elevated serum anti-Müllerian hormone, estradiol, and progesterone levels, decreased serum follicle-stimulating hormone and luteinizing hormone levels, and alleviated ovarian pathology. It reduced the mitochondrial DNA content and mitochondrial membrane potential. Furthermore, it upregulated ATP levels and the mRNA and protein expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1 $\alpha$ ), mitochondrial transcription factor A, and superoxide dismutase 2. In addition, it suppressed NOD-like receptor pyrin domain containing 3, caspase-1, interleukin-1 $\beta$ , and gasdermin D levels in the GCs of POI mice.

<sup>†</sup>Yun Chen, Ying Zhao, and Chenyun Miao are joint first authors of this article.

\*Correspondence: zhaqin01@163.com

Department of TCM Gynecology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, 453 Tiyuchang Road, Xihu District, Hangzhou 310007, Zhejiang Province, China



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

**Conclusions:** Quercetin protected the ovarian reserve from CTX-induced ovarian damage by reversing mitochondrial dysfunction and activating mitochondrial biogenesis via the PGC1- $\alpha$  pathway. Moreover, quercetin may improve ovarian functions by downregulating pyroptosis in the CTX-induced POI model. Thus, quercetin can be considered a potential agent for treating POI.

**Keywords:** Premature ovarian insufficiency, Cyclophosphamide, Quercetin, Mitochondria, Pyroptosis

## Background

With the aging of the population, the number of people with tumors has increased globally, including in women of reproductive age. Many chemotherapeutic drugs used for cancer treatment often exhibit serious gonadal-toxic effects [1]. Exposure to chemotherapy is regarded as a specific risk factor for premature ovarian insufficiency (POI), resulting in menstrual disorders, metabolic abnormalities, and infertility [2]. Although chemotherapeutic drugs inhibit the growth and spread of tumors, the quality of life and reproductive ability of female patients are susceptible to adverse effects.

Cyclophosphamide (CTX), a chemotherapeutic drug commonly used to treat various forms of cancer, causes apparent damage to the ovaries with dose-dependent effects [3, 4]. Recent studies have demonstrated that CTX-induced ovary damage is associated with the facilitation of granulosa cell (GC) apoptosis [5]. GCs, the largest cell group in the ovary, are responsible for the synthesis of estrogen and progesterone and are closely involved in follicle development, ovulation, and atresia [6]. The growth rate of GCs can affect the transcriptional activity of oocytes, which is regulated by the gap junctions between them [7, 8]. An experimental study confirmed that the apoptosis level of GCs in a POI model group was substantially higher than that in the normal group [9]. In contrast, increased inflammatory factor levels and decreased antioxidant capacity play a fundamental role in CTX-induced ovary damage [10, 11].

Reactive oxygen species (ROS) are a double-edged sword. Certain levels of ROS are essential for typical female physiological processes, such as oocyte maturation and fertilization, embryo development, and pregnancy [12]. Oxidative stress (OS), resulting from the excessive generation of ROS and defective antioxidant defense mechanisms, is believed to be the primary cause of GC apoptosis [13]. The toxic effects of CTX are due to its active metabolites, which can hinder DNA synthesis and interfere with the antioxidant defense mechanisms of the ovary, resulting in the overproduction of the ROS malondialdehyde (MDA) [14].

Mitochondria are the main site of ROS production; hence, they are a primary target of ROS, which can lead to fatal consequences [15]. For example, hydroxyl radicals, a common ROS, can damage mitochondrial

DNA (mtDNA) and oxidize mitochondrial proteins and lipids [16]. Moreover, the release of ROS and mtDNA is a critical upstream event that triggers the activation of NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome. NLRP3 induces a rapid, inflammatory form of programmed cell death called pyroptosis, accompanied by enhanced secretion of interleukin (IL)-1 $\beta$  and IL-18 [17]. Previous studies have shown that oxidative stress activates inflammasomes in oocytes and GCs [18, 19].

However, there are no widely recognized protective agents. Thus, a new approach is required to prevent ovarian damage from chemotherapy drugs, preserve future fertility, maintain female endocrine function, and avoid the long-term complications of POI.

Quercetin is a natural flavonoid that is widely found in many fruits and plants, including tea, onions, apples, and kale [20]. Owing to its high solubility and bioavailability, it has been widely studied for its therapeutic and preventive effects on various diseases [21]. Several studies have demonstrated its excellent safety and efficacy in multiple cancers, Alzheimer's disease, and metabolic diseases [22–24]. Quercetin has potent antioxidant and anti-inflammatory properties [25]. Interestingly, several *in vitro* and *in vivo* studies have reported the correlation between the antioxidant activity of quercetin and POI [26, 27]. However, the mechanism through which quercetin inhibits OS in CTX-induced ovarian dysfunction remains unclear.

This study used a CTX-induced POI mouse model to explore whether quercetin could improve ovarian function by suppressing OS and activating mitochondrial biogenesis. Furthermore, we explored the possible anti-pyroptosis properties of quercetin in alleviating ovarian damage following CTX exposure.

## Results


**Quercetin lowered follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels and increased anti-Müllerian hormone (AMH), estradiol (E2), and progesterone (P) expression**

We employed enzyme-linked immunosorbent assays (ELISAs) to detect serum FSH, LH, AMH, E2, and P expression levels. The mice in the CTX group had higher FSH and LH levels than those in the control (Con) group,

and these levels declined significantly with quercetin intervention (Fig. 1c and d). The CTX group showed decreased AMH, E2, and P expression than those in the Con group. After medium- and high-dose quercetin intervention, AMH, E2, and P levels were all clearly elevated (Fig. 1a, b, and e). **These findings suggest that quercetin can increase the expression of sex hormones and AMH in a dose-dependent manner to facilitate functional ovarian recovery.**

#### Quercetin significantly improved ovarian tissue pathology

After hematoxylin and eosin (H&E) staining, the ovarian tissue morphology was observed under a microscope. The ovaries in the Con group had a large number of corpora lutea and visible follicles at all levels. The ovaries of the CTX group were much smaller than those of the Con group, with fewer primary and secondary follicles, and some atretic follicles. Compared with the CTX group, all the treated groups exhibited an increased in the number




**Fig. 1** ELISA detection of serum levels of E<sub>2</sub>, P, AMH, FSH, and LH in mice of different groups. Serum (a) E<sub>2</sub>, (b) P, (c) FSH, (d) LH, and (e) AMH levels. FSH: follicle-stimulating hormone; LH: luteinizing hormone; AMH: anti-Müllerian hormone; E<sub>2</sub>: estradiol; P: progesterone. All data are expression as mean ± standard deviation mean (


of primary follicles. Particularly, in the medium- (QueM) and high-dosage (QueH) quercetin groups, the number of growing follicles at all levels increased, those of atretic follicles decreased, and numerous GCs in mature follicles were neatly arranged in a radial pattern (Fig. 2). These data indicate the potential of quercetin in improving ovarian tissue pathology and increasing the number of ovarian follicles in a dose-dependent manner. **Quercetin protected against oxidative damage in mice with POI**

The levels of total antioxidant capacity (T-AOC), serum superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), MDA, and ROS in each group were assessed

to determine the effects of quercetin on oxidative damage. The T-AOC content was substantially lower in the CTX group than in the Con group, and it was elevated in QueM and QueH groups (Fig. 3a). The SOD and GSH-Px contents in the CTX group were the lowest among all the groups. Following quercetin treatment, a dose-dependent increase was observed in GSH-Px content (Fig. 3b and c). Unlike antioxidant enzymes such as SOD and GSH-Px, MDA is the final product of ROS accumulation. As expected, MDA content was higher in the CTX group than in the Con group. Compared with the CTX group, all the treated groups, except the low-dosage quercetin (QueL) group, exhibited a significant decrease in MDA content (Fig. 3d). ROS are crucial products of



**Fig. 2** Ovarian tissue pathology assessment in mice of each group. **a** Representative photography by Hematoxylin & Eosin (40 ×, 100 ×, and 400 ×). The black, blue, red and white arrows indicate primary follicles, secondary follicles, antral follicles and atretic follicles respectively. **b** follicle counting. PF: primordial follicle; PrF: primary follicles; SF: secondary follicles; AnF: antral follicles; AF: atretic follicles. All data are expression as mean ± standard deviation mean (




oxidative stress. Maximum ROS production was detected in the CTX group, whereas mitochondrial ROS production was notably decreased in the QueM and QueH groups (Fig. 3e). These findings demonstrate the ability of quercetin to increase T-AOC, SOD, and GSH-Px levels and decrease MDA and ROS levels in the ovarian tissues, implying that it can function as an antioxidant in mice with POI.

**Quercetin enhanced mitochondrial function in the GCs**

**of POI mice**

To further explore the antioxidant mechanism of quercetin, we measured mtDNA production, ATP production, and mitochondrial membrane potential (MMP) levels,

which are effective indicators of mitochondrial function. The number of mtDNA copies in the CTX group was significantly reduced. The mtDNA copy levels increased to different extents in all the intervention groups, of which the QueH and coenzyme 10-treated (Q10) groups displayed the best effect (Fig. 4a). Compared with the Con group, ATP production in the GCs of the CTX group was significantly reduced. Following quercetin treatment, ATP production increased in a dose-dependent manner compared to the CTX group (Fig. 4b). The CTX group had a higher rate of MMP reduction than the Con group (Fig. 4c). Following quercetin intervention, the results showed a dose-dependent decrease in the MMP reduction rate compared to the Con group (Fig. 4c and d). In



addition, we evaluated the morphology of the mitochondria in the GCs of each group. Most of the mitochondria in the Con group were well-developed, and the crest structures were visible. In the CTX group, severe mitochondrial edema and cristae appeared broken or were non-existent. The mitochondrial edema in the QueM and QueH groups was reduced, with minor structural disorders in mitochondrial cristae. These findings highlight the ability of quercetin to reduce MMP reduction rate and increase mtDNA synthesis and ATP production in the GCs of POI mice, resulting in an improved mitochondrial function.

#### **Quercetin improved mitochondrial redistribution**

##### **in the GCs of POI mice**

The mitochondria in the Con group were well-developed; the cristae were clearly visible and aggregated and were distributed near the nucleus. However, the mitochondria in the CTX group were swollen compared to those in the Con group, with mitochondrial cristae disappearing or becoming vacuolated. The number of intracellular vacuolated mitochondria was reduced and the number of normal mitochondria were increased in all the quercetin and Q10 groups (Fig. 5). These findings indicate that quercetin can improve mitochondrial redistribution, leading to improved mitochondrial activity.

**Quercetin upregulated peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1 $\alpha$ ), mitochondrial transcription factor A (TFAM), and SOD2 expression at the mRNA and protein levels in the GCs**

##### **of POI mice**

The mRNA and protein levels of TFAM, PGC1 $\alpha$ , and SOD2 in the ovarian GCs of mice were lower in the CTX group than in the Con group (Figs. 6 and 7). Moreover, the mRNA and protein levels of TFAM, PGC1, and SOD2 were considerably higher in the QueM, QueH, and Q10 groups than in the CTX group (Figs. 6 and 7). These data demonstrate the ability of quercetin to promote the mRNA and protein levels of TFAM, PGC1 $\alpha$ , and SOD2, leading to the improved mitochondrial function of GCs.

**Quercetin reduced the protein expression of NLRP3, gasdermin D (GSDMD), caspase-1, and IL-1 $\beta$  in the GCs**

##### **of POI mice**

To confirm that pyroptosis is involved in POI progression, we examined NLRP3, GSDMD, caspase-1, and IL-1 $\beta$  expression. The results revealed that compared with the Con group, the CTX group had considerably higher levels of these proteins, and treatment with quercetin and coenzyme Q10 reduced the levels of these proteins (Fig. 8). These findings indicate that quercetin inhibits pyroptosis by diminishing NLRP3, GSDMD,

caspase-1, and IL-1 $\beta$  protein expression in the GCs of POI mice.


#### **Discussion**

The findings of the present study indicate that quercetin supplementation protects the ovarian reserve from CTX-induced ovarian damage, resulting in the elevation of serum AMH, E2, and P levels, reduction of FSH and LH expression, and alleviation of ovarian pathology. Further, quercetin displayed a protective function, reflected by the increase in ATP levels, mtDNA copy number, and MMP, and the upregulation of PGC1 $\alpha$ , SOD2, and TFAM at both the mRNA and protein levels. In addition, quercetin may exert an anti-pyroptosis potential by suppressing NLRP3, caspase-1, IL-1 $\beta$ , and GSDMD levels in the GCs of POI mice.

We first established a POI mouse model by injecting CTX (90 mg/kg dose). Various dosages and procedures have been used to induce POI in animals [28, 29]. CTX is the most commonly used chemotherapeutic drug. The ovary, in particular, is negatively affected by CTX in female reproductive organs. Its hazardous side effects are linked to its active metabolites, which interfere with ovarian antioxidant defense mechanisms and cause ROS via conjugating with glutathione to disrupt DNA synthesis [30]. According to our results, CTX can lead to a significant decrease in the number of both the primary and secondary follicles, and the ovarian volume in the model mice was smaller than that in the control mice. These results were consistent with those of a previous study that established a POI model by CTX injection [31–34]. AMH is the most accurate biomarker of ovarian aging [35] and is primarily secreted by ovarian GCs. FSH and LH are crucial hormones for ovarian development, and the FSH/LH ratio is regarded as an independent factor for predicting pre-POI and early ovarian decline [36]. In addition to its well-known roles, FSH also regulates the expression of E2 and P, both of which act as important markers for ovarian GC maturation [37]. Thus, they can also be utilized as ovarian reserve markers.

In the present study, the serum AMH, E2, and P levels in the model group were significantly decreased. Simultaneously, morphological degradation of the ovarian tissue was observed under a light microscope after H&E staining. Following quercetin administration for 28 days, the AMH, E2, and P levels were significantly elevated, accompanied by a reduction in the degradation of follicles at all stages. Increases in the levels of ovarian reserve markers and morphological changes suggest that quercetin has a favorable effect on rebuilding ovarian function following CTX exposure.


GCs are the main source of steroid hormones including E2 and P [38], then they influence FSH and LH via



**Fig. 5** Mitochondrial ultrastructure under the transmission electron microscopy in mouse granulosa cells of each group. **a** transmission electron microscopy characterization of mitochondria. Green and blue arrows indicate normal mitochondria, irregular mitochondria respectively. Scale bar: 500 nm. **b** percentage normal and abnormal mitochondria. All data are expression as mean  $\pm$  standard deviation mean (

feedback regulation. Hence, we believe that viability of GCs is the key role of the effect of quercetin on production or inhibition of sex-related hormones. Quercetin is indeed confirmed that affect the proliferation and the apoptosis of GCs [38]. To further explore the underlying mechanisms we went to investigate the effect of quercetin on GCs from the perspective of OS and pyroptosis.

Accumulating evidence has revealed the significance of ROS in triggering mitochondrial dysfunction. After POI progression, excessive ROS causes the oxidative damage of proteins, nucleic acids, and lipids, ultimately leading to cell death [39]. MDA is the final lipid peroxidation product [40] and T-AOC refers to the total antioxidative capacity. In contrast, SOD, along with GSH-Px, is an effective ROS scavenger. Increased levels of ROS reflect




the ability to resist oxidative damage [41]. In the induced POI model, the expression of oxidative stress products (ROS, T-AOC, and MDA) increased, whereas that of antioxidant products (SOD and GSH-Px) decreased.

After quercetin treatment, the oxidative stress levels dramatically declined. High doses of quercetin, especially 50 mg/kg, exerted a protective effect against oxidative stress by exhibiting antioxidant abilities in the CTX-induced ovarian damage model, which was consistent with previous research [42].

The represents the quantity and quality of ovarian follicle composed of GCs and oocytes [43]. The role of mitochondria in ovarian reserve is due primarily to ATP production, which is vital for ovarian cellular function. [44]. mtDNA mutation is the most common biomarkers for mitochondrial dysfunction. clinical researches suggested that mtDNA content in GCs was related to oocyte quality, and mtDNA mutation play a promoting role in the progression and pathogenesis of POI [45, 46]. Moreover, improvement mitochondrial function through supplementation of components of the respiratory chains is considered as a feasible method for recover ovarian reserve [47].


The mitochondria are a significant site for ROS production. Excessive ROS accumulation can damage the mitochondria [48]. Mitochondrial ATP production, MMP, and mtDNA production levels are substantial indicators of mitochondrial function. Multiple studies have shown that excessive ROS damages mtDNA, downregulates MMP, and reduces intracellular ATP levels [49, 50]. Consistent with these findings, our results showed that quercetin reversed the affected mitochondrial functions by increasing ATP and mtDNA production and decreasing the MMP reduction rate. To further investigate mitochondrial oxidative damage, we used transmission electron microscopy (TEM) to determine the mitochondrial ultrastructure. We observed that the decrease in the number of normal mitochondria induced by CTX was reversed by quercetin treatment. These results suggested that quercetin exerts protective effects by enhancing mitochondrial functions to prevent CTX-induced mitochondrial damage. Mitochondrial biogenesis is a complex biological process involving the formation of mitochondrial membranes and the synthesis of mitochondrial proteins and mtDNA [51]. Several studies have shown that quercetin could bolster mitochondrial biogenesis in mammalian cells [52]. PGC1- $\alpha$  is known as the “master regulator” and is involved in mitochondrial biogenesis; it interacts with the nuclear respiratory factors (NRF) (e.i.NRF-1, NRF-2), initiates NRF transcription, followed by the activation of mitochondrial transcription factor A (TFAM). TFAM is crucial for the replication of mtDNA and the transcription of mitochondria-encoded genes, resulting in mitochondrial generation [53–55]. The close relationship between PGC1- $\alpha$  and OS resistance has been indicated by diverse studies in the liver, brain, muscle tissue, or cell lines [56–59]. A few studies have reported that quercetin



promotes mitochondrial biogenesis in GCs. Thus, we speculated that quercetin might suppress ovarian damage via the PGC1-α pathway. The results analyzed using western blotting and RT-qPCR supported our speculation that quercetin increases the expression of PGC1-α, TFAM, and SOD2 in the QueM and QueH groups.

Recent evidence has demonstrated the role of mitochondrial ROS in inflammasome activation [60, 61]. ROS could act like the “kindling” or triggering factor to activate NLRP3 inflammasomes, resulting in inflammatory pathological processes [19]. The NLRP3 inflammasome is a multiprotein complex formed by apoptosis-associated speck-like protein (ASC), NLRP3, and procaspase-1 [62]. Activation of NLRP3 facilitates the induction of the downstream effector caspase-1, which subsequently triggers the excessive release of IL-1β and IL-18, ultimately initiating programmed pyroptosis. As a rapid form of host cell death, pyroptosis is involved in the progression of various diseases that are characterized by cell swelling, membrane pore formation, membrane rupture, and the extensive release of inflammatory cytokines [63–66].

Based on the existing finding of excessive ROS expression in the POI model resulting in ovarian damage, we hypothesized that pyroptosis might occur in the ovarian tissue after the CTX injection. We detected the protein expression of inflammasome components (NLRP3, caspase-1, IL-1β) as well as GSDMD. Our results indicated that the quantities of these pyroptosis-related proteins were considerably higher in the CTX group than those in the control. Treatment with quercetin and coenzyme Q10 decreased the expression of these proteins, which is consistent with our previous hypothesis that quercetin protects against ovarian ROS damage through the anti-pyroptosis pathway, in addition to its antioxidant activity. It is worth pointing out that autophagy may be the intermediate link connecting ROS and pyroptosis [67]. ROS accumulation and mitochondrial dysfunction can trigger autophagy/mitophagy that clear up damaged mitochondria and controlling mitochondrial mass [68]. First, ROS is an important activating factor for NLRP3 inflammasome, so autophagy can reduce NLRP3-dependent pyroptosis by the clearance of ROS



**Fig. 8** NLRP3, caspase-1, GSDMD, and IL-1 $\beta$  protein expression in granulosa cells of each group. Original blots/gels are provided separately. **a** protein band, **(b)** protein expression of NLRP3, **(c)** protein expression of Caspase-1, **(d)** protein expression of GSDMD, and **(e)** protein expression of IL-1 $\beta$ . NLRP3: NOD-like receptor pyrin domain containing 3; GSDMD: gasdermin D. All data are expression as mean  $\pm$  standard deviation mean

in damaged mitochondria [67]. Moreover, various autophagy-related proteins can inhibit secretion of IL-1 $\beta$  and cell lysis in pyroptosis [69]. Research found that blocked autophagy enhanced the activation of the NLRP3-dependent pyroptosis in chronic cerebral hypoperfusion [70], but the relationship between ROS, autophagy, and pyroptosis in POI is still unclear and worthy to be explored in our future studies.

Interestingly, coenzyme Q10 showed an effect similar to that of high-dose quercetin. This may be because coenzyme Q10 plays a crucial role as an electron carrier inside the mitochondrial electron transport chain [71] and directly mediates the expression of several genes inside the mitochondria, including those involved in inflammation [67, 72]. This also illustrates the excellent protective capacity of quercetin against oxidative stress and mitochondrial ability from another perspective. The main limitation of the present study is the lack of in vitro experiments to validate the present results;

hence, further in vitro investigation is needed in the future.

## Conclusions

In summary, we demonstrated that mitochondrial dysfunction contributes to POI pathogenesis. Quercetin administration reverses mitochondrial dysfunction by inducing antioxidant damage and activating mitochondrial biogenesis through the PGC1- $\alpha$  pathway. Moreover, our study proved our hypothesis that quercetin protects ovarian function by downregulating pyroptosis in a CTX-induced POI model. These results indicate that quercetin can be considered a potential agent for treating POI.

## Methods

### Animals

C57BL/6 female mice (6–8 weeks old) were purchased from the Shanghai SLAC Laboratory Animal Company (Certificate No. SCXK 2013–0018, Shanghai, China) and

housed in the barrier system of the Animal Experiment Center, located in Zhejiang Chinese Medical University, under pathogen-free conditions,  $22 \pm 2$  °C, and 12 h light/dark cycle with lights on at 7:00 a.m. The Institutional Animal Care and the Animal Experiment Center of the Zhejiang Chinese Medical University approved all the experimental procedures used in this study (approval number: IACUC-20180402-02).

#### Experimental grouping and model establishment

After an acclimatization period (5–7 days), a 10-day estrous cycle detection was implemented to exclude mice with abnormal ovarian functions. Then, 36 female mice were randomly and equally distributed into six groups: A: Con (control group); B: CTX (CTX model group); C: QueL (low-dosage quercetin group, 12.5 mg/kg); D: QueM (medium-dosage quercetin group, 25 mg/kg); E: QueH (high-dosage quercetin group, 50 mg/kg); F: Q10 (Coenzyme Q10 group, 1.25 mg/kg). The mice in the Con group received a single intraperitoneal injection of 200  $\mu$ L saline, while the others were administered an equal volume of saline containing 90 mg/kg CTX (GC111451, Glpbio, Montclair, USA), a dose reported to lead to an ovarian immune disturbance that causes diminished ovarian reserve in mice [73]. After one-time intraperitoneal injection of CTX with a dose of 90 mg/kg, vaginal exfoliated cell smears were performed at 8:00 a.m. daily for two weeks, and the model establishment was regarded as successful if the irregular estrous cycle was observed. The Con and CTX groups were intragastrically administered normal saline. In contrast, the quercetin groups were administered various concentrations of quercetin solution (12.5–50 mg/kg) at 8:00 a.m., the doses of quercetin were determined based on previous studies [74, 75], and the Q10 group was perfused with 1.25 mg/kg coenzyme Q10. After four consecutive

weeks, the mice were sacrificed by CO<sub>2</sub> exposure 48 h after the administration of 10 IU of pregnant mare serum gonadotropin.

#### Extraction of primary ovarian GCs

After the mice were sacrificed, the ovaries of the mice were washed with phosphate-buffered saline (PBS), and the surrounding fat tissue was removed; F12 medium was added to the petri dish, and the follicles were punctured using a sterile 1-mL syringe needle to release the GCs into the medium. The cells in the Pasteur tube were gently blown and centrifuged at  $100 \times g$  for 3 min after they were filtered using a 200-mesh cell sieve. The supernatant was discarded, the complete medium was added and the cells were transferred to a new sterile petri dish and then placed in a 37 °C incubator for cultivation at 5% CO<sub>2</sub>.

#### ELISA

SOD, GSH-Px, T-AOC, MDA, E<sub>2</sub>, FSH, LH, P, and AMH levels were detected using specific ELISA kits (Maiman, Jiangsu, China) according to the manufacturer's instructions.

#### Histopathology and ultrastructural morphology evaluations

After the mice were sacrificed, the ovary tissues were removed and fixed in 4% paraformaldehyde, followed by dehydration, paraffin embedding, and serial sectioning. Ovary sections with a thickness of 4  $\mu$ m were obtained and stained with H&E on glass slides. Images of the ovary structure and follicle counts were obtained using a microscope (Nikon Eclipse E100). For observing the mitochondrial morphology, immediately after dissection, the ovary tissue was fixed with glutaraldehyde and osmic acid, dehydrated through a series of graded ethanol solutions, and then ingrained in a resin mixture. Ultrathin sections were cut to a thickness of 100 nm and stained with lead citrate and uranyl acetate. TEM images of mitochondrial morphology were obtained using a Hitachi 7650 TEM instrument.

#### Assessment of ROS levels

The six-well plate was filled with 10 M 2'-7'-dichlorofluorescein diacetate to completely cover the GCs, which were subsequently incubated for 20 min at 37 °C in a cell incubator. The GCs were washed and suspended in 100  $\mu$ L of PBS, and the fluorescence intensity of ROS was detected by flow cytometry (BD FACSVerser, BD Biosciences).

To assess changes in the MMP, JC-1 (Beyotime Institute of Biotechnology, Shanghai, China) was used as a fluorescent probe. GCs were collected and stained with JC1 staining solution for 30 min at 37 °C, and flow cytometry (BD FACSVerser, BD Biosciences) was used to evaluate the samples.

#### Assessment of MMP

#### Quantification of ATP levels

The chemiluminescence ATP assay kit was used as per the manufacturer's instructions (Beyotime Institute of Biotechnology). The reagents to be used in an ice bath were melted, the ATP standard solution was diluted with ATP detection lysate to several concentrations of 0.1, 0.3, 1, 3, and 10  $\mu$ M, and the corresponding standard curve was drawn. Subsequently, 100  $\mu$ L of ATP detection working solution was added into the detection hole at 20–25 °C. Subsequently, 20  $\mu$ L of the standard or sample was immediately added to each well and

**Table 1** Primer sequences

Gene	Mouse	Forward primer (5'-3')	Reverse primer (3'-5')
TFAM		AAC ACC CAG ATG CAA AAC TTTCA	GAC TTG GAG TTA GCT GCT CTTT
Mouse PGC1 $\alpha$		GAC AGC TTT CTG GGT GGA TTG	GGA GAC TGG GCC GTT TAG T
Mouse SOD2		CAG ACC TGC CTT ACG ACT ATGG	CTC GGT GGC GTT GAG ATT GTT
Mouse mtDNA		AAC CTG GCA CTG AGT CAC CA	GGG TCT GAG TGT ATA TAT CAT GAA GAG AAT
Mouse GAPDH		TCA ACG GCA CAG TCA AGG	TGA GCC CTT CCA CGATG
Mouse $\beta$ -globin		CCC TTG GAC CCA GAG GTT CT	AGT ACC GTT CTT TCA CGA GC

mixed. After at least 2 s, the relative light unit value was obtained using a Glomax 20/20 luminometer (Promega Corporation, Madison, WI, USA) and a standard curve was used to compute the concentration of ATP.

#### Quantitative real-time PCR

Quantitative real-time PCR was performed to detect the mtDNA copy number and the content of SOD2, PGC1- $\alpha$ , and TFAM. Total RNA was extracted from the GCs and reverse-transcribed into cDNA. SYBR Premix Ex Taq<sup>TM</sup> TM II (Perfect Real Time) (TaKaRa, Shiga, Japan) was used to detect the expression of the specified genes. The following conditions were used for reverse transcription: 42 °C for 15 min, 85 °C for 5 s, cooling to 4 °C for 10 min, and refrigeration at -20 °C. The reverse transcription reaction mixture was added to the tubes used for quantitative fluorescence reaction, and the amplification reaction conditions were as follows: pre-denaturation at 95 °C for 10 min, followed by 40 cycles (95 °C for 15 s and 60 °C for 60 s). The results of the reaction were collected, and normalized expression was calculated as the relative fold change using the 2<sup>- $\Delta\Delta$ CT</sup> method. Table 1 shows the primer sequences used for quantitative real-time PCR of the genes. GAPDH was used as the internal reference gene.

#### Western blotting

The GCs were lysed on ice in radioimmunoprecipitation buffer (Beyotime Institute of Biotechnology), and the protein content was determined using the bicinchoninic acid Protein Assay Kit (Solarbio, Beijing, China) on a 4–12% gel subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis (Biosharp, Beijing, China). After electrophoresis and transfer to polyvinylidene difluoride membranes, the membranes were blocked with bovine serum albumin and incubated overnight at 4 °C with primary antibodies against TFAM, PGC1 $\alpha$ , SOD2, NLRP3, GSDMD, IL-1 $\beta$ , and caspase-1 [64] (Cell Signaling Technology, Danvers, MA, USA) diluted at 1:1000.  $\beta$ -Actin (1:1000, Cell

Signaling Technology) was used as the internal reference. The membranes were washed thrice with Tris-buffered saline with Tween-20 (TBST), and the blots were detected using an enhanced chemiluminescence (ECL) substrate system after a 1-h incubation with secondary antibodies (Cell Signaling Technology). The blots were analyzed using ImageJ 1.8.0.

#### Statistical analyses

All experiments were replicated more than three times, and the data are reported as the mean  $\pm$  standard deviation (SD). All groups were analyzed for multiple comparisons by one-way analysis of variance (ANOVA) using Prism 8.0.2. Additionally, statistical significance was set at  $P < 0.05$  and  $P < 0.01$ .

#### Abbreviations

CTX: Cyclophosphamide; POI: Primary ovarian insufficiency; ELISA: Enzyme-linked immunosorbent assay; MMP: Mitochondrial membrane potential; PGC1 $\alpha$ : Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; TFAM: Mitochondrial transcription factor A; SOD: Superoxide dismutase; NLRP3: NOD-like receptor pyrin domain containing 3; GSDMD: Gasdermin D; GC: Granulosa cell; OS: Oxidative stress; ROS: Reactive oxygen species; mtDNA: Mitochondrial DNA; IL-1 $\beta$ : Interleukin-1 $\beta$ ; PBS: Phosphate-buffered saline; GSH-Px: Glutathione peroxidase; T-AOC: Total antioxidant capacity; MDA: Malondialdehyde; E2: Estradiol; FSH: Follicle-stimulating hormone; LH: Luteinizing hormone; P: Progesterone; AMH: Anti-Müllerian hormone; H&E: Hematoxylin and eosin; TEM: Transmission electron microscopy; TBST: Tris-buffered saline with Tween-20; SD: Standard deviation; ANOVA: One-way analysis of variance.

#### Acknowledgements

Not applicable.

#### Authors' contributions

Y.C., Y.Z., and C.Y.M. designed and performed most experiments, and wrote the manuscript. L.Q.Y. analyzed the data and edited the manuscript. R.Y.W. helped design the animal experiments. B.X.C. analyzed the histology and histopathology. L.Q.Y. helped edit the manuscript. Q.Z. supervised all experiments, and edited the manuscript. All authors read and approved the final manuscript.

#### Funding

This work was financially supported by grants from the Program for Medical Key Discipline of Hangzhou-Gynecology of Traditional Chinese Medicine (2020SJZDXK02), the Medical and Health Science and Technology Plan of Zhejiang Province (2021KY920), and the Basic Public Welfare Research Program of Zhejiang Province (LGF22H27019).

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author (zhaqin01@163.com) on reasonable request.

**Declarations**

**Ethics approval and consent to participate** Ethics approval was obtained from the Institutional Animal Care and the Animal Experiment Center of the Zhejiang Chinese Medical University (approval number: IACUC-20180402-02). Consent to participate is not applicable for this study. **Consent for publication** Not applicable. **Competing interests** The authors declare that they have no competing interests. **Received: 25 August 2022 Accepted: 16 December 2022**

Published online: 27 December 2022

**References**

- Sonigo C, Beau I, Binart N, Grynberg M. The impact of chemotherapy on the ovaries: Molecular aspects and the prevention of ovarian damage. *Int J Mol Sci.* 2019;20:5342.
- European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L, Davies M, Anderson R, Bartlett J, Braat D, et al. ESHRE Guideline: Management of women with premature ovarian insufficiency. *Hum Reprod.* 2016;31:926–37.
- Overbeek A, van den Berg MH, van Leeuwen FE, Kaspers GJ, Lambalk CB, van Dulmen-den BE. Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: A systematic review. *Cancer Treat Rev.* 2017;53:10–24.
- de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. *Clin Pharmacokinet.* 2005;44:1135–64.
- Yuksel A, Bildik G, Senbabaoglu F, Akin N, Arvas M, Unal F, et al. The magnitude of gonadotoxicity of chemotherapy drugs on ovarian follicles and granulosa cells varies depending upon the category of the drugs and the type of granulosa cells. *Hum Reprod.* 2015;30:2926–35.
- Kranc W, Brązert M, Ożegowska K, Nawrocki MJ, Budna J, Celichowski P, et al. Expression profile of genes regulating steroid biosynthesis and metabolism in human ovarian granulosa cells—A primary culture approach. *Int J Mol Sci.* 2017;18:2673.
- Fu Y, Jiang H, Liu JB, Sun XL, Zhang Z, Li S, et al. Genome-wide analysis of circular RNAs in bovine cumulus cells treated with BMP15 and GDF9. *Sci Rep.* 2018;8:7944.
- Chang HM, Qiao J, Leung PC. Oocyte-somatic cell interactions in the human ovary—novel role of bone morphogenetic proteins and growth differentiation factors. *Hum Reprod Update.* 2016;23:1–18.
- Park HS, Chugh RM, El Andaloussi A, Hobeika E, Esfandyari S, Elsharoud A, et al. Human BM-MSC secretome enhances human granulosa cell proliferation and steroidogenesis and restores ovarian function in primary ovarian insufficiency mouse model. *Sci Rep.* 2021;11:4525.
- Melekoglu R, Ciftci O, Eraslan S, Cetin A, Basak N. Beneficial effects of curcumin and capsaicin on cyclophosphamide-induced premature ovarian failure in a rat model. *J Ovarian Res.* 2018;11:33.
- Luo Q, Yin N, Zhang L, Yuan W, Zhao W, Luan X, et al. Role of SDF-1/CXCR4 and cytokines in the development of ovary injury in chemotherapy drug induced premature ovarian failure mice. *Life Sci.* 2017;179:103–9.
- Agarwal A, Aponte-Mellado A, Premkumar BJ, Shaman A, Gupta S. The effects of oxidative stress on female reproduction: A review. *Reprod Biol Endocrinol.* 2012;10:49.
- Agarwal A, Saleh RA, Bedaiwy MA. Role of reactive oxygen species in the pathophysiology of human reproduction. *Fertil Steril.* 2003;79:829–43.
- Helsby NA, Yong M, van Kan M, de Zoysa JR, Burns KE. The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes. *Br J Clin Pharmacol.* 2019;85:1925–34.
- Sinha K, Das J, Pal PB, Sil PC. Oxidative stress: The mitochondria-dependent and mitochondria-independent pathways of apoptosis. *Arch Toxicol.* 2013;87:1157–80.
- Orrenius S, Gogvadze V, Zhivotovsky B. Mitochondrial oxidative stress: Implications for cell death. *Annu Rev Pharmacol Toxicol.* 2007;47:143–83.
- Yang L, Chen Y, Liu Y, Xing Y, Miao C, Zhao Y, et al. The role of oxidative stress and natural antioxidants in ovarian aging. *Front Pharmacol.* 2020;11:617843.
- Wang Y, Li C, Ali I, Li L, Wang G. N-acetylcysteine modulates non-esterified fatty acid-induced pyroptosis and inflammation in granulosa cells. *Mol Immunol.* 2020;127:157–63.
- Hou J, Lei Z, Cui L, Hou Y, Yang L, An R, et al. Polystyrene microplastics lead to pyroptosis and apoptosis of ovarian granulosa cells via NLRP3/Caspase-1 signaling pathway in rats. *Ecotoxicol Environ Saf.* 2021;212:112012.
- Rauf A, Imran M, Khan IA, Ur-Rehman M, Gilani SA, Mehmood Z, et al. Anticancer potential of quercetin: A comprehensive review. *Phytother Res.* 2018;32:2109–30.
- Xu D, Hu MJ, Wang YQ, Cui YL. Antioxidant activities of quercetin and its complexes for medicinal application. *Molecules.* 2019;24:1123.
- Reyes-Farias M, Carrasco-Pozo C. The anti-cancer effect of quercetin: Molecular implications in cancer metabolism. *Int J Mol Sci.* 2019;20:3177.
- Khan H, Ullah H, Aschner M, Cheang WS, Akkol EK. Neuroprotective effects of quercetin in Alzheimer's disease. *Biomolecules.* 2019;10:59.
- Shabbir U, Rubab M, Daliri EB, Chelliah R, Javed A, Oh DH. Curcumin, quercetin, catechins and metabolic diseases: The role of gut microbiota. *Nutrients.* 2021;13:206.
- Boots AW, Haenen GR, Bast A. Health effects of quercetin: From antioxidant to nutraceutical. *Eur J Pharmacol.* 2008;585:325–37.
- Yao X, Mei Y, Mao W. Quercetin improves mitochondrial function and inflammation in H<sub>2</sub>O<sub>2</sub>-induced oxidative stress damage in the gastric mucosal epithelial cell by regulating the PI3K/AKT signaling pathway. *Evid Based Complement Alternat Med.* 2021;2021:1386078.
- Wang J, Qian X, Gao Q, Lv C, Xu J, Jin H, et al. Quercetin increases the antioxidant capacity of the ovary in menopausal rats and in ovarian granulosa cell culture in vitro. *J Ovarian Res.* 2018;11:51.
- Yamchi NN, Rahbarghazi R, Bedate AM, Mahdipour M, Nouri M, Khanbabaee R. Menstrual blood CD146+ mesenchymal stem cells reduced fibrosis rate in the rat model of premature ovarian failure. *Cell Biochem Funct.* 2021;39(8):998–1008.
- Spears N, Lopes F, Stefansdottir A, et al. Ovarian damage from chemotherapy and current approaches to its protection. *Hum Reprod Update.* 2019;25(6):673–93.
- Tsai-Turton M, Luong BT, Tan Y, Luderer U. Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion. *Toxicol Sci.* 2007;98(1):216–30.
- Dehghani F, Aboutalebi H, Esmaeilpour T, Panjehshahin MR, Bordbar H. Effect of platelet-rich plasma (PRP) on ovarian structures in cyclophosphamide-induced ovarian failure in female rats: A stereological study. *Toxicol Mech Methods.* 2018;28:653–9.
- Khedr NF. Protective effect of mirtazapine and hesperidin on cyclophosphamide-induced oxidative damage and infertility in rat ovaries. *Exp Biol Med (Maywood).* 2015;240:1682–9.
- Jiang M, Wang W, Zhang J, Wang C, Bi Y, Li P, et al. Protective effects and possible mechanisms of actions of Bushen Cuyun recipe on diminished ovarian reserve induced by cyclophosphamide in rats. *Front Pharmacol.* 2020;11:546.
- Sefrioui O, Madkour A, Aboulmaouahib S, Kaarouch I, Louanjli N. Women with extreme low AMH values could have in vitro fertilization success. *Gynecol Endocrinol.* 2019;35:170–3.
- Huang J, Lin J, Gao H, Wang Y, Zhu X, Lu X, et al. Anti-Mullerian hormone for the prediction of ovarian response in progestin-primed ovarian stimulation protocol for IVF. *Front Endocrinol (Lausanne).* 2019;10:325.
- Jiao X, Meng T, Zhai Y, Zhao L, Luo W, Liu P, et al. Ovarian reserve markers in premature ovarian insufficiency: Within different clinical stages and different etiologies. *Front Endocrinol (Lausanne).* 2021;12:601752.
- La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: From theory to practice. *Hum Reprod Update.* 2014;20:124–40.
- Rashidi Z, Khosravizadeh Z, Talebi A, Khodamoradi K, Ebrahimi R, Amidi F. Overview of biological effects of Quercetin on ovary. *Phytother Res.* 2021;35(1):33–49.

39. Sytykiewicz H, Łukasik I, Goławska S, Chrzanowski G. Aphid-triggered changes in oxidative damage markers of nucleic acids, proteins, and lipids in maize (*Zea mays* L.) seedlings. *Int J Mol Sci.* 2019;20:3742.
40. Luo Q, Cheng D, Huang C, Li Y, Lao C, Xia Y, et al. Improvement of colonic immune function with soy isoflavones in high-fat diet-induced obese rats. *Molecules.* 2019;24:1139.
41. Chen Y, Liu H, Huang H, Ma Y, Wang R, Hu Y, et al. Squid ink polysaccharides protect human fibroblast against oxidative stress by regulating NADPH oxidase and connexin43. *Front Pharmacol.* 2019;10:1574.
42. Lu XL, Zhao CH, Yao XL, Zhang H. Quercetin attenuates high fructose feeding-induced atherosclerosis by suppressing inflammation and apoptosis via ROS-regulated PI3K/AKT signaling pathway. *Biomed Pharmacother.* 2017;85:658–71.
43. Jamil Z, Fatima SS, Ahmed K, Malik R. Anti-Mullerian Hormone: Above and Beyond Conventional Ovarian Reserve Markers. *Dis Markers.* 2016;2016:5246217.
44. Wang T, Zhang M, Jiang Z, Seli E. Mitochondrial dysfunction and ovarian aging. *Am J Reprod Immunol.* 2017;77(5):<https://doi.org/10.1111/aji.12651>.
45. Ding Y, Xia BH, Zhuo GC, Zhang CJ, Leng JH. Premature ovarian insufficiency may be associated with the mutations in mitochondrial tRNA genes. *Endocr J.* 2019;66(1):81–8.
46. Boucret L, Chao de la Barca JM, Morinière C, et al. Relationship between diminished ovarian reserve and mitochondrial biogenesis in cumulus cells. *Hum Reprod.* 2015;30(7):1653–64.
47. Yang Q, Cong L, Wang Y, et al. Increasing ovarian NAD<sup>+</sup> levels improve mitochondrial functions and reverse ovarian aging [published correction appears in *Free Radic Biol Med.* 2022 Feb, 1(179), pp. 433–434]. *Free Radic Biol Med.* 2020;156:1–10.
48. Wang P, Deng J, Dong J, Liu J, Bigio EH, Mesulam M, et al. TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response. *PLoS Genet.* 2019;15:e1007947.
49. Tai H, Jiang XL, Song N, Xiao HH, Li Y, Cheng MJ, et al. Tanshinone IIA combined with cyclosporine A alleviates lung apoptosis induced by renal ischemia-reperfusion in obese rats. *Front Med (Lausanne).* 2021;8:617393.
50. Du ZD, Wei W, Yu S, Song QL, Liu K, Gong SS. NADPH oxidase 2-mediated insult in the auditory cortex of Zucker diabetic fatty rats. *Neural Plast.* 2019;2019:3591605.
51. Wang Y, Kang Y, Qi C, Zhang T, Zhao H, Ji X, et al. Pentoxifylline enhances antioxidant capability and promotes mitochondrial biogenesis for improving age-related behavioral deficits. *Aging (Albany, NY).* 2020;12:25487–504.
52. de Oliveira MR, Nabavi SM, Braidly N, Setzer WN, Ahmed T, Nabavi SF. Quercetin and the mitochondria: A mechanistic view. *Biotechnol Adv.* 2016;34:532–49.
53. Fontecha-Barriuso M, Martin-Sanchez D, Martinez-Moreno JM, Monsalve M, Ramos AM, Sanchez-Niño MD, et al. The role of PGC-1 $\alpha$  and mitochondrial biogenesis in kidney diseases. *Biomolecules.* 2020;10:347.
54. Wang Y, Zhao X, Lotz M, Terkeltaub R, Liu-Bryan R. Mitochondrial biogenesis is impaired in osteoarthritis chondrocytes but reversible via peroxisome proliferator-activated receptor  $\gamma$  coactivator 1 $\alpha$ . *Arthritis Rheumatol.* 2015;67:2141–53.
55. Li PA, Hou X, Hao S. Mitochondrial biogenesis in neurodegeneration. *J Neurosci Res.* 2017;95:2025–9.
56. Houghton MJ, Kerimi A, Tumova S, Boyle JP, Williamson G. Quercetin preserves redox status and stimulates mitochondrial function in metabolically-stressed HepG2 cells. *Free Radic Biol Med.* 2018;129:296–309.
57. Liu P, Zou D, Yi L, Chen M, Gao Y, Zhou R, et al. Quercetin ameliorates hypobaric hypoxia-induced memory impairment through mitochondrial and neuron function adaptation via the PGC-1 $\alpha$  pathway. *Restor Neurol Neurosci.* 2015;33:143–57.
58. Kim CS, Kwon Y, Choe SY, Hong SM, Yoo H, Goto T, et al. Quercetin reduces obesity-induced hepatosteatosis by enhancing mitochondrial oxidative metabolism via heme oxygenase-1. *Nutr Metab (Lond).* 2015;12:33.
59. Rayamajhi N, Kim SK, Go H, Joe Y, Callaway Z, Kang JG, et al. Quercetin induces mitochondrial biogenesis through activation of HO-1 in HepG2 cells. *Oxid Med Cell Longev.* 2013;2013:154279.
60. Xu X, Zhang L, Ye X, Hao Q, Zhang T, Cui G, et al. Nrf2/ARE pathway inhibits ROS-induced NLRP3 inflammasome activation in BV2 cells after cerebral ischemia reperfusion. *Inflamm Res.* 2018;67:57–65.
61. Harijith A, Ebenezer DL, Natarajan V. Reactive oxygen species at the crossroads of inflammasome and inflammation. *Front Physiol.* 2014;5:352.
62. He K, Zhu X, Liu Y, Miao C, Wang T, Li P, et al. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development. *Oncotarget.* 2017;8:37657–72.
63. Lu F, Lan Z, Xin Z, He C, Guo Z, Xia X, et al. Emerging insights into molecular mechanisms underlying pyroptosis and functions of inflammasomes in diseases. *J Cell Physiol.* 2020;235:3207–21.
64. Horng T, Hotamisligil GS. Linking the inflammasome to obesity-related disease. *Nat Med.* 2011;17:164–5.
65. Song Z, Gong Q, Guo J. Pyroptosis: Mechanisms and links with fibrosis. *Cells.* 2021;10:3509.
66. Wang D, Weng Y, Zhang Y, Wang R, Wang T, Zhou J, et al. Exposure to hyperandrogen drives ovarian dysfunction and fibrosis by activating the NLRP3 inflammasome in mice. *Sci Total Environ.* 2020;745:141049.
67. Biasizzo M, Kopitar-Jerala N. Interplay Between NLRP3 Inflammasome and Autophagy. *Front Immunol.* 2020;11:591803.
68. Ikeda Y, Shirakabe A, Brady C, Zablocki D, Ohishi M, Sadoshima J. Molecular mechanisms mediating mitochondrial dynamics and mitophagy and their functional roles in the cardiovascular system. *J Mol Cell Cardiol.* 2015;78:116–22.
69. Saitoh T, Fujita N, Jang MH, et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1 $\beta$  production. *Nature.* 2008;456(7219):264–8.
70. Su SH, Wu YF, Lin Q, Wang DP, Hai J. URB597 protects against NLRP3 inflammasome activation by inhibiting autophagy dysfunction in a rat model of chronic cerebral hypoperfusion. *J Neuroinflammation.* 2019;16(1):260.
71. Rezaabakhsh A, Rahbarghazi R, Malekinejad H, Fathi F, Montaseri A, Garjani A. Quercetin alleviates high glucose-induced damage on human umbilical vein endothelial cells by promoting autophagy. *Phytomedicine.* 2019;56:183–93.
72. Hargreaves I, Heaton RA, Mantle D. Disorders of human coenzyme Q10 metabolism: An overview. *Int J Mol Sci.* 2020;21:6695.
73. Huang C, Song K, Ma W, Ding J, Chen Z, Zhang M. Immunomodulatory mechanism of Bushen Huoxue Recipe alleviates cyclophosphamide-induced diminished ovarian reserve in mouse model. *J Ethnopharmacol.* 2017;208:44–56.
74. Velázquez KT, Enos RT, Narsale AA, et al. Quercetin supplementation attenuates the progression of cancer cachexia in ApcMin/+ mice. *J Nutr.* 2014;144(6):868–75.
75. Tripathi A, Kumar B, Sagi SSK. Prophylactic efficacy of Quercetin in ameliorating the hypoxia induced vascular leakage in lungs of rats. *PLoS ONE.* 2019;14(6):e0219075.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”). Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer Nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

[onlineservice@springernature.com](mailto:onlineservice@springernature.com)